Document is current
Any future updates will be listed below
-
Authors
Farma, Jeffrey M.
Olszanski, Anthony J.
Messina, Jane L.
Sondak, Vernon K.
- License Information
-
More Information
Article History
Received: 12 September 2024
Accepted: 11 October 2024
First Online: 4 November 2024
Disclosure
: No one other than the authors provided any financial or material support for or influenced the content of this manuscript. The authors report the following financial interests: JMF: none; AO: consultant to Bristol Myers Squibb, IO Biotech, Oncosec, Pfizer, and Replimune and research funding from Anaveon, Antegene, Glaxo Smith Kline, HiFiBio, Immatics, Johnson & Johnson, Kezar, Lantern, Regeneron, Replimune, Shionogi, SpringBank, Takeda, Viewpoint; JLM: none; VKS: consultant to Bristol Myers Squibb, Genesis Drug Discovery & Development, Iovance, Merck, Mural Oncology, Novartis and Sun Pharmaceuticals; research funding from Neogene Therapeutics, Skyline and Turnstone.
Free to read: This content has been made available to all.
